Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility

Recruiting now

Conditions studied: Fertility

In brief

The goal of this observational study is to evaluate whether supplementation with the Ovosicare® Fertility food supplement increases the possibility of becoming pregnant in women aged between 32 and 38 years who have been trying to become pregnant for at least 6 months before starting supplementation.

Key facts

Study ID

NCT07083999

Run by

Procare Health Iberia S.L.

People needed

300

Starts

2025-02-13

Expected to finish

2026-12-01

Last updated by the study team

2025-07-24

Who can join

Age: 32 and older, up to 38. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• - Women who agree to participate in the study by signing the informed consent.
• - Between 32 and 38 years old.
• - Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months.

You may not qualify if…

• - BMI > 30 kg/m2.
• - Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of:
• Azoospermia
• Progressive motility <25%
• Normal morphology ≤2%
• - Pregnant or breastfeeding women.
• - Patients with type 1 diabetes or thyroid disease.
• - Patients with any assisted reproduction technique scheduled during the duration of the study.
• - Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month.
• - Patients with a known allergy to any of the components of Ovosicare® Fertility.
• - Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult.
• - Patients with suspected endometriosis.
• - Existence of fibroids affecting the endometrial cavity.
• - Patients with 2 or more previous abortions.
• - Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.

Where it is running

• Centro Ginecológico Bolonia — Zaragoza, Spain (enrolling)
• HU de Getafe — Getafe, Madrid, Spain (enrolling)
• Clínica Rv Benalmádena — Benalmádena, Malaga, Spain (enrolling)
• H García Orcoyen — Estella-Lizarra, Navarre, Spain (enrolling)
• CP Dr. Andrade Andrade — A Coruña, Spain (enrolling)
• CP Dra. Domenech Casanova — Alicante, Spain (enrolling)
• H Vega Baja de Orihuela — Alicante, Spain (enrolling)
• Clinica Alboran — Almería, Spain (enrolling)
• CP Dr. Aragón Albillos — Almería, Spain (enrolling)
• CM Teknon — Barcelona, Spain (enrolling)
• HU i Politècnic la Fe — Valencia, Spain (enrolling)
• CM Sitges — Sitges, Barcelona, Spain (enrolling)
• HU Vall d'Hebron — Barcelona, Spain (enrolling)
• OBS Ginecólogos Burgos — Burgos, Spain (enrolling)
• Clínica Attella — Castelló, Spain (enrolling)
• CP Dra. Skouri-Bnihech Tioua — Granada, Spain (enrolling)
• CHU Insular - H Materno-Infantil — Las Palmas, Spain (enrolling)
• Clínica Palacios — Madrid, Spain (enrolling)
• Gymeiaka Dra. Oltra Badui — Madrid, Spain (enrolling)
• Gymeiaka Dra. Pavón Sanz — Madrid, Spain (enrolling)
• HU La Paz — Madrid, Spain (enrolling)
• Clínica Imar — Murcia, Spain (enrolling)
• Ancla Clínica Ginecológica — Pontevedra, Spain (enrolling)
• HG de la Santísima Trinidad — Salamanca, Spain (enrolling)
• CP Dra. Sánchez Quintana — Seville, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.